Khondrion, the Dutch biopharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces the initiation of a Phase 1 Clinical Trial with its frontrunner compound KH176. The Trial will be a randomized, double blind, placebo-controlled, dose-escalating study.
Mitochondrial diseases are progressive, often early fatal diseases caused by a defect in the cell’s powerhouses, the mitochondria. “The initiation of the KH176 Phase 1 Trial is a pivotal milestone in the mitochondrial disease drug development program of our company“, said Jan Smeitink, Khondrion’s CEO and Professor of Mitochondrial Medicine at the Radboud University Medical Center, Nijmegen, The Netherlands. “Our Team is very enthusiastic about the fact that this significant milestone has been reached much earlier than expected”.